Ultrasound biomicroscopy in acetazolamide-induced myopic shift with appositional angle closure / Biomicroscopia ultrassônica em mudança miópica induzida por acetazolamida no fechamento de ângulo

ABSTRACT We report a case of a 49-year-old female who presented to the emergency department with blurred vision and vomiting, hours after taking two tablets of 250 mg of acetazolamide. The anterior chamber was bilaterally flat, with normal intraocular pressure in both eyes. An ultrasound biomicroscopic (UBM) examination showed bilateral ciliary effusion and complete appositional angle closure in all quadrants. Acetazolamide-induced bilateral angle closure was diagnosed. Steroid and cycloplegic therapy were initiated, and acetazolamide was discontinued. The following day, the anterior chamber had regained its volume without substantial change in the effusion size. Three weeks later, complete resolution of the ciliary effusion was verified by means of a third UBM scan.

RESUMO Relatamos um caso de uma mulher de 49 anos que se apresentou ao departamento de emergência informando visão borrada e vômitos, horas após ter tomado dois comprimidos de 250 mg de acetazolamida. A câmara anterior era bilateralmente plana com pressão intraocular normal em ambos os olhos. Um exame de biomicroscopia ultrassônica (UBM) mostrou efusão ciliar bilateral e fechamento completo do ângulo aposicional em todos os quadrantes. O bloqueio angular bilateral induzido por acetazolamida foi diagnosticado. O tratamento com esteróides e cicloplégicos foi iniciado e a acetazolamida foi descontinuada. No dia seguinte, a câmara anterior recuperou seu volume sem alterações substanciais no tamanho da efusão. Três semanas depois, a resolução completa da efusão ciliar foi verificada por meio de uma terceira biomicroscopia ultrassônica.

Acetylcholine chloride 1% usage for intraoperative cataract surgery miosis / Cloridrato de Acetilcolina 1% na obtenção da miose intraoperatória na cirurgia de catarata

Abstract Objective: To test the efficacy of Acetylcholine chloride use in obtaining intraoperative miosis on phacoemulsification cataract surgery. Methods: Patients with cataract diagnosis and elected for surgical phacoemulsification procedure were selected. All patients underwent conventional phacoemulsification procedure performed by a single surgeon and all patients had 0.2 ml of Acetylcholine chloride 1% irrigated in the anterior chamber at the end of the surgery. The pupillary diameter was measured immediately before the beginning of surgery, immediately before and two minutes after the use of acetylcholine chloride 1%. Results: A total of 30 eyes from 30 patients were included in the study. 18 were female, and mean age was of 69.5 years with a 7.2y standard deviation on the population study. The mean pupillary diameter immediately before the beginning of surgery was 7.5 mm with a standard deviation of 0.56 mm; the mean pupillary diameter immediately before the acetylcholine chloride 1% use (after the intraocular lens im-plantation) was 7.1 mm with a standard deviation of 0.57 mm. The mean pupillary diameter two minutes after the use of acetylcholine chloride 1% in the anterior chamber was 3.4 mm with standard deviation of 0.66 mm. The mean maximum action time of ACH chloride 1% was 64 seconds, with a standard deviation of 8 seconds. The mean intraocular pressure on the first postoperative day was 19.1 mmHg with a standard deviation of 2.45 mmHg. Conclusion: We conclude that acetylcholine chloride 1% is an important drug to obtaining intraoperative miosis in cataract surgery.

Resumo Objetivo: Demonstrar a eficácia do cloridrato de acetilcolina 1% na obtenção da miose intraoperatória na cirurgia de catarata pela técnica de facoemulsificação. Métodos: Pacientes com diagnóstico de catarata e indicação de cirurgia foram selecionados para participar do presente estudo. Todos os pacientes foram operados pela técnica de facoemulsificação convencional pelo mesmo cirurgião, todos foram submetidos à aplicação de 0,2 ml do cloridrato de acetilcolina 1% na câmara anterior ao final do procedimento cirúrgico. A medida do diâmetro pupilar foi realizada imediatamente antes do início da cirurgia, imediatamente antes do uso do cloridrato de acetilcolina 1% e após 2 minutos. Resultados: Foram estudados 30 olhos de 30 pacientes, destes, 18 eram do sexo feminino, a média de idade do estudo foi de 69,5 anos com desvio padrão de 7,2 anos. A média do diâmetro pupilar imediatamente antes do início da cirurgia foi 7,55 mm com desvio padrão de 0,56mm, a média do diâmetro pupilar imediatamente antes do uso do cloridrato de acetilcolina 1% (após implante da lente intraocular no saco capsular) foi 7,1mm com desvio padrão de 0,57mm. A média do diâmetro pupilar após 2 minutos da aplicação da acetilcolina na câmara anterior foi de 3,4 mm com desvio padrão de 0,66mm. O tempo médio de ação máxima do medicamento foi de 64 segundos, com desvio padrão de 8 segundos. A média da pressão intraocular no primeiro dia do pós-operatório foi de 19,1 mmHg com desvio padrão de 2,45mmHg. Conclusão: O estudo acima mostrou que a acetilcolina apresenta boa eficácia na obtenção de miose intraoperatória na cirurgia de facoemulsificação, permitindo uma maior facilidade na confecções das suturas corneanas ou corneo-escleral, reduzindo a incidência de sinéquias anteriores periféricas. Concluimos que o cloridrato de acetilcolina 1% é um importante medicamento na obtenção da miose intraoperatória na cirurgia de catarata.

Safety and efficacy of intracameral moxifloxacin injection for prophylaxis of endophthalmitis after phacoemulsification / Segurança e eficácia na injeção intracameral de moxifloxacino para profilaxia da endoftalmite após a facomeulsificação

ABSTRACT Purpose: To evaluate the safety and efficacy of 0.05 mL intracameral injection of moxifloxacin in patients who underwent phacoemulsification and intraocular lens (IOL) implant. Methods: Retrospective study comprising patients who underwent phacoemulsification and IOL implant between January 2009 and December 2013. Patients were divided into two groups. Group A followed standard endophthalmitis prevention protocol and group B followed the same protocol plus intracameral injection of 0.05 mL of moxifloxacin hydrochloride at 5.45 mg/mL, immediately after IOL implant. Results: Medical records from 7,195 eyes of 3,751 patients (median age: 67.8 ± 8.96, range: 48-83 years, 53.8% female) were evaluated. Group A included 3,515 eyes of 1,838 patients and group B included 3,680 eyes of 1,913 patients. The incidence of endophthalmitis in group A was 0.22% (8:3,515 eyes) and in group B was 0.03% (1:3,680 eyes, p=0.0198, Fischer's exact test). No toxicity or inflammation related to the use of moxifloxacin was observed. Conclusions: There was a 7.3-fold lower ratio of endophthalmitis in the group that received moxifloxacin intracameral injection. This study provides further evidence that moxifloxacin is an effective intracameral prophylactic antibiotic.

RESUMO Objetivo: Avaliar a segurança e a eficácia da injeção intracameral de 0,05 mL de moxifloxacina em pacientes que realizaram facoemulsificação e implante de lente intraocular. Métodos: Estudo retrospectivo envolvendo pacientes submetidos a facoemulsificação e implante de lente intraocular entre janeiro de 2009 a dezembro de 2013. Os pacientes foram divididos em dois grupos. O grupo A seguiu o protocolo padrão de prevenção de endoftalmite e o grupo B seguiu o mesmo protocolo associado à injeção intracameral de 0,05 mL de cloridrato de moxifloxacino a 5,45 mg/mL, imediatamente após o implante de lentes intra-oculares (LIO). Resultados: Foram avaliados registros clínicos de 7.195 olhos de 3.751 pacientes (mediana de idade de 67,8 ± 8,96, faixa de 48-83 anos, 53,8% de mulheres). O grupo A incluiu 3.515 olhos de 1.838 pacientes e o grupo B incluiu 3.680 olhos de 1.913 pacientes. A incidência de endoftalmite no grupo A foi de 0,22% (8:3.515 olhos) e no grupo B de 0,03% (1:3.680 olhos, p=0,0198, teste exato de Fischer). Não foi observada toxicidade ou inflamação relacionada com o uso de moxifloxacino intracameral. Conclusões: Houve uma proporção 7,3 vezes menor de endoftalmite no grupo que recebeu injeção de moxifloxacino. Este estudo fornece mais evidências que o moxifloxacino intracameral é um antibiótico profilático intracameral eficaz.

Comparison of Cytotoxic Effects on Rabbit Corneal Endothelium between Preservative-free and Preservative-containing Dorzolamide/timolol

PURPOSE: To evaluate and compare the toxic effects of eyedrops containing a fixed combination of 2.0% dorzolamide and 0.5% maleate timolol with or without preservatives on rabbit corneal endothelium. METHODS: This study was performed with 22 eyes of New Zealand white rabbits. Dorzolamide/timolol eyedrops with preservative (Cosopt group) or without preservative (Cosopt-S group) were diluted with a balanced salt solution at a 1 : 1 ratio. We injected 0.1 mL of diluted Cosopt into the anterior chamber of left eyes and an equal volume of diluted Cosopt-S into the anterior chamber of right eyes. Corneal thickness, corneal haze, and conjunctival injection were measured before and 24 hours after treatment. Endothelial damage was compared between both eyes by vital staining (alizarin red/trypan blue staining), live/dead cell assay, TUNEL assay, and scanning electron microscopy. RESULTS: Corneal endothelial damage was severe in the Cosopt group. Cosopt-treated eyes exhibited remarkable corneal edema and prominent apoptosis of endothelial cells. In addition, the live/dead cell assay revealed many dead cells in the endothelium, and scanning electron microscopy analysis showed that corneal endothelial cells exhibited a partial loss of microvilli on the surface as well as extensive destruction of intercellular junctions. However, in the Cosopt-S group, corneal edema was mild and the damage to the corneal endothelium was minimal. CONCLUSIONS: The main cause of corneal endothelial toxicity was due to the preservative in the dorzolamide/timolol fixed combination eyedrops, and not the active ingredient. Thus, it appears to be safer to use preservative-free eyedrops during the early postoperative period.

Pseudohypopyon after Management of Posterior Capsule Rupture Using Intracameral Triamcinolone Injection in Cataract Surgery

No abstract available.

Assessing patient satisfaction with cataract surgery under topical anesthesia supplemented by intracameral lidocaine combined with sedation / Avaliação da satisfação dos pacientes submetidos à facectomia por facoemulsificação realizada com anestesia tópica associada à lidocaína na câmara anterior combinada com sedação

PURPOSE: Ocular akinesia, the use of anticoagulants, and patient collaboration are some of the factors that must be taken into consideration when choosing the appropriate anesthesia for phacoemulsification cataract surgery. The satisfaction of patients with the use of topical anesthesia and conscious sedation for this procedure has not been enough described in Brazil. Conscious sedation allows patient walk and answer a voice command. To assess the satisfaction, pain, and perioperative hemodynamic alterations of patients subjected to phacoemulsification under conscious sedation and topical anesthesia supplemented with intracameral lidocaine. METHODS: Prospective cohort non-controlled study that included patients treated by the same surgical team over a 70-day period. Sedation was performed with midazolam at a total dose of 3 mg and topical anesthesia with 0.5% proxymetacaine chlorhydrate and 2% lidocaine gel combined with 2% lidocaine by intracameral route. The intraoperative vital parameters, scores based on the Iowa Satisfaction with Anesthesia Scale (ISAS), and the pain visual analog scale (VAS) were recorded at several time points after surgery. RESULTS: A total of 106 patients were enroled in study (73.6% female), the mean age was 65.9 years. The surgical procedures lasted 11.2 minutes on average. The hemodynamic parameters did not exhibit significant changes at any of the investigated time points. The average ISAS score was 2.67 immediately after surgery and 2.99 eight hours after the surgery; this increase was statistically significant (p<0.0001). More than two-thirds (68.9%) of the participants (73 patients) did not report any pain in the transoperative period, and 98.1% of patients denied the occurrence of pain after surgery. CONCLUSIONS: Patients that received topical anesthesia supplemented by intracameral lidocaine combined with sedation for phacoemulsification cataract surgery reported adequate level of satisfaction with the anesthetic choice. Furthermore, the patients exhibited hemodynamic parameter stability and pain control.

OBJETIVO: Acinesia ocular, uso de anticoagulantes e cooperação do paciente são fatores envolvidos na escolha da anestesia para cirurgia de catarata por facoemulsificação. A satisfação com anestesia tópica associada à sedação consciente neste procedimento foi pouco descrita no Brasil. Sedação consciente permite que o paciente sedado mantenha a capacidade de deambular e de responder ao chamado de voz. Avaliar a satisfação, dor e alterações hemodinâmicas perioperatórias de pacientes submetidos à facoemulsificação sob sedação consciente por anestesia tópica com injeção de lidocaína na câmara anterior. MÉTODOS: Estudo de coorte prospectivo, não controlado de pacientes operados pela mesma equipe em um período de 70 dias. Realizada sedação com 3 mg de midazolam, anestesia tópica com cloridrato de proximetacaína 0,5% e lidocaína gel 2%, associada à injeção de lidocaína 2% na câmara anterior. Registrados parâmetros vitais intraoperatórios, escala de satisfação com a anestesia de Iowa (ISAS) e a Escala Analógica Visual da Dor (EVA) em diferentes períodos do pós-operatório. RESULTADOS: Foram avaliados 106 pacientes (73,6% do sexo feminino), com idade média de 65,9 anos. O tempo cirúrgico médio foi de 11,2 minutos. Não houve diferença estatisticamente significante entre as variáveis hemodinâmicas nos momentos estudados. Ao final da operação, a média de escores na escala ISAS foi de 2,67 e 8 horas após foi de 2,99, apresentando aumento significativo (p<0,0001). Não houve relato de qualquer dor transoperatória em 68,9% dos casos, e 98,10% dos pacientes negaram dor pós-operatória. CONCLUSÕES: Em cirurgia de facectomia por facoemulsificação realizada sob sedação consciente associada à anestesia tópica com injeção de lidocaína 2% na câmara anterior, obtêm-se níveis adequados de satisfação com a anestesia, estabilidade de variáveis hemodinâmicas durante o procedimento e adequado controle da dor.

Intracapsular dexamethasone implant in patients undergoing phacoemulsification and intraocular lens implantation / Implante intracapsular de dexametasona em pacientes submetidos a facoemulsificação e implante de lente intraocular

PURPOSE: To relate the outcomes of 7 eyes of 7 patients in which a dexamethasone 0.7 mg implant (Ozurdex®) was placed inside the capsule bag after phacoemulsification and intraocular lens (IOL) implantation and compare with the fellow eyes, that were operated by the same technique and received dexamethasone eyedrops in the post-operatory. METHODS: Report review of 7 eyes of 7 patients who received dexamethasone 0.7 mg implant after phacoemulsification and IOL, comparing them to the fellow eyes. All the patients underwent bilateral cataract surgery, with one month interval, by the same technique and by experienced surgeons, without complications. Post operatory medication consisted of moxifloxacin eye drops for all the 14 eyes and topic dexamethasone for the 7 eyes that did not received the implant. RESULTS: Nuclear cataract classification (according to LOCS III) was 3.28 ± 0.69 in the implant eye group and 3.14 ± 0.83 in the fellow eye group. Postoperative best spectacle correct visual acuity (BSCVA) was 0.85 ± 0.12 and 0.87 ± 0.13, respectively in the implant and fellow eye groups. The intraocular pressure remained stable and similar to the pre-operative measurements. Anterior chamber reaction and cornea edema were similar in both groups in the follow-up. Two of the four no sutured pellet migrated to the anterior chamber during the first post-operative week and had to be repositioned. Another no sutured pellet dislocated and remained partially inside the capsule bag. The 3 patients with IOL haptic-sutured pellet had no complications. CONCLUSIONS: In the present study, dexamethasone 0.7mg implant were effective in controlling the inflammation after phacoemulsification and IOL implantation, with no significant side effects.

OBJETIVOS: Relatar os resultados de 7 olhos de 7 pacientes em que foi realizado o implante de dexametasona 0,7 mg (Ozurdex®) no saco capsular após facoemulsificação e implante de lente intraocular (LIO) e comparar com os olhos contralaterais, que foram operados pela mesma técnica e receberam colírio de dexametasona no pós-operatório. MÉTODOS: Relato de casos de 7 olhos de 7 pacientes que receberam o implante de dexametasona 0,7 mg após facoemulsificação e implante de LIO, comparando-os com os olhos contralaterais. Todos os pacientes foram submetidos a cirurgia de catarata bilateral, com intervalo de um mês entre as cirurgias, pela mesma técnica, por cirurgiões experientes e sem complicações. No pós-operatório foi utilizado colírio de moxifloxacino em todos os 14 olhos e dexametasona tópica nos olhos que não receberam o implante. RESULTADOS: A classificação da catarata de acordo com o LOCS III foi de 3,28 ± 0,69 no grupo que recebeu o implante e 3,14 ± 0,83 no grupo de olhos contralateral. A acuidade visual com melhor correção foi de 0,85 ± 0,12 e 0,87 ± 0,13 respectivamente nos grupos com e sem implante. A pressão intraocular permaneceu estável e similar aos valores pré-operatórios. A reação de câmara anterior e o edema de córnea foram similares nos dois grupos. Dois dos 4 implantes sem sutura migraram para a câmara anterior durante a primeira semana de pós-operatório e necessitaram de reposicionamento. Outro implante sem sutura teve deslocamento e permaneceu parcialmente dentro do saco capsular. Os 3 pacientes com implante suturado não tiveram complicações. CONCLUSÃO: No presente estudo, o implante de dexametasona 0,7 mg foi efetivo no controle da inflamação intraocular após cirurgia de facoemulsificação e implante de LIO, sem efeitos colaterais significativos.

Efficacy and Safety of Intracameral Moxoft Eye Drops (Moxifloxacin Ophthalmic Solution 0.5%) for Endophthalmitis Prophylaxis in Cataract Surgery.

Objective: To evaluate the efficacy and safety of intracameral Moxoft eye drops (Moxifloxacin ophthalmic solution 0.5%) administered at the conclusion of phacoemulsification cataract surgery for the purpose of endophthalmitis prophylaxis. Design: Open label, multicentre, prospective. Setting: Three ophthalmologists across India. Methods: A total of 134 outpatients of either sex undergoing phacoemulsification with no ocular pathology other than cataract and meeting all inclusion/exclusion criteria were enrolled in the study. All patients received preoperatively 1 drop of Moxoft eye drops (Moxifloxacin ophthalmic solution 0.5%) topically every 15 minutes atleast 4 times one hour prior to surgery. 0.1 ml moxifloxacin solution was aspirated into the tuberculin syringe and injected into the capsular bag under the capsulorhexis edge after completion of the Phacoemulsification and IOL implantation. Post-operative treatment was as per standard protocol. Patients were assessed pre-operatively and on day 1, day 7 & day 30 after surgery for ocular symptom scores for pain in eyes, ocular discharge, hazy cornea, conjunctival hyperemia, and hypopyon and chemosis. Anterior chamber (AC) reaction was graded (if present) on all the visits with fixed slit-lamp settings and on 5-point rating scale for AC flare and cells in AC. Global assessment was done for efficacy and tolerability at the end of therapy on a 3-point scale. Result: Thirteen patients were excluded from the analysis due to insufficient data and an intentionto- treat analysis was done for efficacy on 121 patients. There was significant reduction in scores of pain in eyes, conjunctival hyperemia, mean AC flare, mean AC cells (p<0.0001 for all) and ocular discharge (p=0.018). Hypopyon and/or corneal endothelial cell damage was observed in none of the patients. Therapy was rated good to excellent on efficacy and tolerability parameters with no reporting of a poor rating. Conclusion: Moxoft eye drops (Moxifloxacin ophthalmic solution 0.5%) is safe for use by intracameral administration with no corneal decompensation. Tolerability and post-operative results were found to be excellent.

Effect of tropicamide and homatropine eye drops on a-scan parameters of the phakic normal eyes

A prospective study to evaluate the changes in A-Scan axial parameters of phakic normal eyes before and after instillation of 1% topical Tropicamide and 2% Homatropine eye drops. Anterior chamber depth, lens thickness, vitreous chamber length, and ocular axial length were measured in 76 eyes before and after cycloplegia induced by 1% topical Tropicamide, and in 28 eyes with 2% Homatropine eye drops. Anterior chamber depth demonstrated increase from baseline readings with Tropicamide and Homatropine eye drops, while lens thickness showed decrease from the baseline readings with both eye drops. Effect of both the eye drops on over all axial length and vitreous chamber length is statistically seen, but is clinically negligible and not significant. Cycloplegia induced by 1% Tropicamide eye drops and 2% Homatropine eye drops has a significant measurable influence on anterior chamber depth and lens thickness, while vitreous chamber length and overall axial length demonstrated negligible statistical difference on A-Scan parameters of the normal phakic eyes

Acute-Onset Bilateral Myopia and Ciliochoroidal Effusion Induced by Hydrochlorothiazide

The authors experienced two cases of hydrochlorothiazide (HCTZ)-induced acute-onset bilateral myopia and shallowing of the anterior chambers. Two middle-aged women taking HCTZ, a sulfa derivative, visited our clinic complaining of acute bilateral visual deterioration. Both had good visual acuity without corrective lenses before taking HCTZ. A complete ophthalmologic examination revealed bilateral myopic shift, intraocular pressure elevation, shallowing of the anterior chambers, choroidal effusions, radiating retinal folds, and conjunctival chemosis. Approximately one week after HCTZ discontinuance, all ocular changes disappeared completely. Physicians should be aware of the adverse ocular effects of HCTZ and should manage patients accordingly.

Comparison of corneal endothelial cell loss during phacoemulsification using continuous anterior chamber infusion versus those using ophthalmic viscosurgical device: randomized controlled trial.

AIM: We conducted this study to evaluate and compare corneal endothelial cell loss between phacoemulsification with continuous anterior chamber infusion using anterior chamber maintainer (ACM) and phacoemulsification using ophthalmic viscosurgical device (OVD). MATERIALS AND METHODS: This was a prospective, randomized controlled trial. Fifty eyes of 47 patients of senile cataract undergoing phacoemulsification were included. Patients were randomly allocated into two groups of 25 eyes each. Cataract surgery was performed by phacoemulsification with anterior chamber (AC) continuous infusion with balanced salt solution (BSS) plus and ACM without OVD in Group A, and in Group B, phacoemulsification was performed using OVD with BSS plus. Corneal endothelial cell count and pachymetry were performed preoperatively and postoperatively on day 1, day 7, and day 30. The mean increase in pachymetry was 4.86%, 2.94%, and 1.94%, (Group A) and 5.95%, 3.94%, and 0.51%, (Group B) on first, seventh, and 30 th postoperative day respectively. The difference between the percentage increase in pachymetry between the two groups was not significant at day 1 ( P = 0.441), day 7 ( P = 0.298), and day 30 ( P =0.174) postoperatively. The density of endothelial cells decreased postoperatively (day 30) by 7.38% (Group A) and 7.47% (Group B) without any significant statistical difference ( P = 0.983) between two groups. CONCLUSION: Use of ACM for continuous AC infusion and omission of OVD during phacoemulsification did not cause significant difference in corneal swelling or endothelial cell loss in the immediate postoperative period up to one month.

Manual small incision cataract surgery under topical anesthesia with intracameral lignocaine: study on pain evaluation and surgical outcome.

The authors here describe manual small incision cataract surgery (MSICS) by using topical anesthesia with intracameral 0.5% lignocaine, which eliminates the hazards of local anesthesia, cuts down cost and time taken for the administration of local anesthesia. AIMS: To evaluate the patients' and surgeons' experience in MSICS using topical anesthesia with intracameral lignocaine in terms of pain, surgical complications, and outcome. SETTINGS AND DESIGN: Prospective interventional case series. MATERIALS AND METHODS: Ninety-six patients of senile cataract were operated by MSICS under topical anesthesia with intracameral lignocaine using "fish hook technique." The patients and the single operating surgeon were given a questionnaire to evaluate their experience in terms of pain, surgical experience, and complications. STATISTICAL ANALYSIS USED: Statistical analysis software "Analyseit." RESULTS: There were 96 patients enrolled in the study. The mean pain score was 0.7 (SD +/- 0.97, range 0-5, median 0.0, and mode 0.0). Fifty-one patients (53%) had pain score of zero, that is, no pain. Ninety-one patients (approximately 95%) had a score of less than 3, that is, mild pain to none. All the surgeries were complication-free except one and the surgeon's experience was favorable in terms of patient's cooperation, anterior chamber stability, difficulty, and complications. The ocular movements were not affected, and hence, the eye patch could be removed immediately following the surgery. CONCLUSIONS: MSICS can be performed under topical anesthesia with intracameral lignocaine, which makes the surgery patient friendly, without compromising the outcome.

Acute myopia and angle closure caused by topiramate, a drug used for prophylaxis of migraine.

Acute transient myopia with shallowing of the anterior chamber is a rare idiosyncratic response to many systemic and topical medications, including sulfonamides. Several such cases have been reported in the past, but are less frequently reported in recent times. We report a case of acute progressive myopia and bilateral angle closure due to Topiramate--a drug used for epilepsy and migraine prophylaxis.

Comparison between preservative free lidocaine 1% anterior chamber irrigation [intracameral], continuous retro-bulbar anesthesia and the standard retro-bulbar anesthesia in anterior segment ocular surgery for Yemeni patients

To compare the effect of preservative free lidocaine 1% anterior chamber irrigation [intracameral] with topical anesthesia, continuous retro-bulbar anesthesia and standard retro-bulbar anesthesia in cataract surgery. 81 patients were subject to cataract extraction, with or without glaucoma surgery. Patients underwent full systemic and ocular examination prior to surgery. Blood analysis, liver and kidney function were also done. The first group included 25 eyes and were operated with preservative free lidocajne 1% anterior chamber irrigation [intracameral] after Benoxinate topical anesthesia. The second group included 22 eyes and were operated with continuous retro-bulbar anesthesia using retro-bulbar cannula. The third group included 34 eyes and were operated with standard retro-bulbar anesthesia. Patients in the first group experienced minimal discomfort and good tolerance to microscope light. Patients in the second group experienced some distress by the continuous touch of the retro-bulbar cannula, which was mal-directed in a few cases. Patients in the third group experienced some anxiety and pain with prolongation of surgical time. Preservative free lidocaine 1% anterior chamber irrigation after topical anesthesia seems to be an excellent method comparable to the standard retro-bulbar anesthesia in anterior segment ocular surgery. Continuous retro-bulbar anesthesia offers pain free post-operative period especially required for qat withdrawal effect

Effects of intracameral carbachol and acetylcholine on early postoperative intraocular pressure after cataract extraction

We performed a randomized, prospective study to evaluate the effect of intraoperative, intracameral carbachol or acetylcholine on early postoperative intraocular pressure(IOP) after extracapsular cataract extraction(ECCE) and posterior chamber lens(PCL) implantation. Fifty-six eyes of 56 patients scheduled for routine ECCE and PCL implantation were randomly assigned into three groups: (1)carbachol infusion (19 eyes) (2) acetylcholine infusion (15 eyes) (3)balanced salt solution (BSS) infusion (control, 22 eyes). We compared the preoperative IOP, early postoperative IOP, postoperative 24 hours IOP and postoperative 1 week IOP. In the measurement of early postoperative IOP, IOP was measured at least twice at 3, 6 or 9 hours postoperatively. There was no significant difference in IOP between the three groups preoperatively, at postoperative 3 hours, and 1 week. At postoperative 6 hours, both the carbachol infusion group and acetylcholine infusion group were significantly different from the BSS infusion group. At postoperative 9 and 24 hours, only carbachol infusion group had a significant difference from BSS infusion group in suppression of postoperative IOP increase. Our results suggest that intraoperative, intracameral administration of carbachol or acetylcholine prevents early postoperative IOP increase, and that carbachol has a more lasting effect.

Effects of sodium hyaluronate on filtration bleb in rabbits

Sodium hyaluronate can be used during a trabeculectomy to prevent early postoperative hypotony and shallow anterior chamber. To determine its long-term effect on the outcome of filtration surgery, fifteen rabbits underwent a osterior-lip sclerectomy in both eyes. Into their right eyes 0.2ml sodium hyaluronate, and into left eyes 0.2ml balanced salt solution were injected intracamerally. Gross and histopathological differences of bleb were observed. There was no statistically significant difference in longevity of the filtration bleb.

Ultrasonic study to see the effect of topical pilocarpine and homatropine on anterior chamber depth in phakic cases.

Pilocarpine and Homatropine are the drugs having known effect on the depth of anterior chamber. The purpose of this study was to demonstrate the time of onset, peak effect and its duration of action as well as shallowing/deepening of the anterior chamber, after single instillation of pilocarpine 2% or homatropine bromide 2%, topically in one eye. Also we tried to see if there is any effect on the contralateral eye, due to systemic absorption of pilocarpine, homatropine after topical instillation of the drug in one eye. Pilocarpine causes a measurable shallowing of the anterior chamber with onset of effect with in 20 minutes and a peak in 60 minutes, the average narrowing being 0.26 mm. (range 0.20-0.29 mm.). Homatropine has a measurable deepening effect on the anterior chamber, due to axial flattening of the lens because of cycloplegia, with a range of 0.33 to 0.36 mm. In 70% of the cases the effect passes away with in 24 hours., but in 30% it comes to normal in 48 hours.

Effect of topical Corticosteroids on the angle of anterior chamber in rabbit eyes

The steroid glaucoma is well-established clinically, however, the mechanism by which the corticosteroids can elevate the I.O.P. has not been fully determined. Thirty two rabbits, were chosen for this work and examined before drug application, then they were classified into two groups. The animals responded to steroid therapy in many ways as growth changes I.O.P. changes and histological as well as histochemical changes. Systemic side effects of the topical dexamethasone 0.1% eye drops were observed as weight loss and subsequent death in some animals. The contralateral [untreated control eyes] showed insignificant rise of I.O.P. and no changes in their histological or histochemical pictures. The rise of I.O.P. was obvious in steroid treated eye and was maintained by continuation of therapy. This rise of I.O.P. was associated with histological and histochemical changes in the angle as shown by different staining processes. The histological and histochemical changes were observed in the aqueous outflow passages mainly in the pectinate ligaments and trabecular region. Furthermore, these changes became more obvious by the increase in time of therapy. In the present work, accumulation of acidic mucopolysaccharides, deposition of fibrinois materilas and presence of active fibroblasts with increased cellularity were discerned. Some eyes showed weakened pectinate ligament fibres and destructed trabecular lamellae after steroid therapy. The conclusion of this study is that the steroid induced glaucoma was not due to a certain individual effect, but it was most probably attributed to multiple effects of steroids. More investigations and experimental studies are still needed to evaluate how much each factor can affect the ocular response to steroids in cortisone glaucoma

Effect of gamma-interferon on fibroblast proliferation and collagen synthesis after glaucoma filtering surgery in white rabbits

Failure of a glaucoma filtering operation mainly results from scarring at the filtering wound, and postoperative proliferation and migration of fibroblasts play an important role histologically in the formation of scar tissue. As an inhibitory agent for fibroblast proliferation, gamma-interferon has been introduced, and the application of gamma-interferon following filtering surgery is now being made on a trial basis. We studied the effect of gamma-interferon histologically on the fibroblast proliferation and collagen synthesis occurring at the filtering site by comparing the effect of gamma-interferon on the experimental group with that of 5-fluorouracil on the control group, using 10 rabbits (20 eyes) after posterior lip sclerectomy. Both groups showed similar flat and diffused bleb grossly and also showed a similar inhibitory effect on fibroblast proliferation and collagen fiber synthesis histologically. Our findings seem to justify the clinical use of gamma-interferon. Further studies on adequate dosage, method of administration, and local and systemic complications would be desired.